NANOMICRO(SH:688690)2024-07-26 09:51Financial Performance - The company expects to achieve a net profit attributable to shareholders of approximately RMB 45.04 million for the first half of 2024, an increase of about RMB 13.21 million or 41.51% compared to the same period last year [3]. - The company anticipates a net profit of approximately RMB 36.52 million after deducting non-recurring gains and losses for the first half of 2024, representing an increase of about RMB 17.18 million or 88.83% year-on-year [9]. - The company's revenue for the first half of 2023 was RMB 295.16 million, with a net profit attributable to shareholders of RMB 31.83 million [10][20]. - The company projects a revenue of approximately RMB 339.77 million for the first half of 2024, an increase of about RMB 44.61 million or 15.12% compared to the same period last year [18]. Product Sales - The sales revenue of chromatography fillers and chromatography media products is expected to be approximately RMB 199.40 million for the first half of 2024, a year-on-year decrease of about 5.46% [22]. - The company completed the acquisition of 44.80% equity in Zhejiang Fuli Analytical Instrument Co., which contributed approximately RMB 57.05 million to the consolidated revenue for the reporting period [13]. Research and Development - The company's R&D investment for the first half of 2024 is approximately RMB 77.08 million, accounting for about 22.68% of its revenue [22]. - The company launched innovative products such as nucleic acid synthesis carrier microspheres and the next-generation affinity chromatography medium NMab Titan in the first half of 2024 [22]. Cost Management - The company has reduced its share-based payment expenses to approximately RMB 22.90 million, a decrease of about 63.86% compared to the same period last year [2]. Performance Forecast - The company has not identified any significant uncertainties that would affect the accuracy of this performance forecast [23].